HI
VRTX icon

Humankind Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Humankind Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,864
Closed -$1.12M – 146
2025
Q3 		$1.12M Buy
2,864
+375
+15% +$157K 0.26% 50
2025
Q2 		$1.11M Buy
2,489
+494
+25% +$228K 0.27% 49
2025
Q1 		$967K Sell
1,995
-72
-3% -$33.6K 0.25% 56
2024
Q4 		$832K Buy
2,067
+152
+8% +$70.5K 0.21% 61
2024
Q3 		$891K Sell
1,915
-24
-1% -$11.5K 0.32% 53
2024
Q2 		$909K Sell
1,939
-89
-4% -$38.6K 0.24% 57
2024
Q1 		$848K Sell
2,028
-236
-10% -$99.8K 0.22% 55
2023
Q4 		$921K Sell
2,264
-44
-2% -$16.3K 0.27% 52
2023
Q3 		$803K Sell
2,308
-39
-2% -$13.6K 0.33% 44
2023
Q2 		$826K Buy
2,347
+432
+23% +$146K 0.32% 44
2023
Q1 		$603K Buy
1,915
+123
+7% +$36.9K 0.25% 63
2022
Q4 		$517K Sell
1,792
-100
-5% -$30.5K 0.22% 66
2022
Q3 		$548K Buy
1,892
+56
+3% +$16.1K 0.26% 60
2022
Q2 		$517K Buy
1,836
+35
+2% +$9.37K 0.25% 61
2022
Q1 		$470K Sell
1,801
-379
-17% -$89.9K 0.19% 68
2021
Q4 		$479K Buy
2,180
+352
+19% +$68.4K 0.6% 55
2021
Q3 		$332K Buy
1,828
+663
+57% +$129K 0.51% 65
2021
Q2 		$235K Buy
+1,165
New +$244K 0.42% 73

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Humankind Investments's VRTX Position: Q4 2025 in Review

Humankind Investments sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 2,864 shares — an estimated $1.12M sold.

Humankind Investments first reported a position in VRTX in Q2 2021 and held it in 18 quarters. The position peaked at $1.12M in Q3 2025. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Humankind Investments reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Humankind Investments sold 2,864 Vertex Pharmaceuticals shares in Q4 2025, an estimated $1.12M.
  • Humankind Investments first reported a position in Vertex Pharmaceuticals in Q2 2021 and held it in 18 quarters.
  • Humankind Investments's Vertex Pharmaceuticals position peaked at $1.12M in Q3 2025.
  • 1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Humankind Investments's 13F filing for Q4 2025, filed 17 Feb 2026.